Drugs / litronesib

Trials 7 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 14 trials
Phase 1 NCT01358019 May 2011 → Jan 2013 cancer Kyowa Kirin, Inc. Completed No outcome recorded
Phase 1 NCT01214655 Jun 2008 → Feb 2011 acute leukemia Eli Lilly and Company Terminated No outcome recorded
Phase 1 NCT01214642 May 2008 → Dec 2011 Eli Lilly and Company Completed No outcome recorded
Phase 1 NCT01214629 Jul 2007 → May 2012 cancer of unknown primary site, metastatic malignant neoplasm Eli Lilly and Company Completed No outcome recorded
Phase 23 trials
Phase 2 NCT01416389 Aug 2011 → Aug 2012 breast cancer Eli Lilly and Company Completed No outcome recorded
Phase 2 NCT01059643 Apr 2011 → Dec 2012 colorectal cancer, esophageal cancer, gastric cancer, head and neck cancer +3 Eli Lilly and Company Completed No outcome recorded
Phase 2 NCT01025284 Dec 2009 → Jul 2012 small cell lung carcinoma Eli Lilly and Company Completed No outcome recorded

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 9 sources stand behind the page.

FieldValueCited text
Known as litronesib “A phase 1 and dose-finding study of LY2523355 (litronesib), an Eg5 inhibitor, in Japanese patients with advanced solid tumors.” PMID 24752449 Apr 2014
Known as KF 89617 ChEMBL registry synonym — accepted as the source's own label CHEMBL2105661
Known as LY2523355 ClinicalTrials.gov intervention name — accepted as the source's own label NCT01025284
6

NCT01214655

NCT01358019

NCT01214642

NCT01214629

NCT01416389

NCT01059643

Action Inhibit “LY2523355 (litronesib) is an allosteric inhibitor of Eg5.” PMID 24752449 Apr 2014
1

“Kinesin-like protein 1 inhibitor” CHEMBL2105661

Modality Small molecule CHEMBL2105661
Route Intravenous “Administered intravenously as a 1-hour infusion” NCT01025284
Target KIF11 “Kinesin-like protein 1 inhibitor” CHEMBL2105661